Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2018Biomarker ResearchOpen Access

EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies

View Full Paper
Ask AI
Bookmark
Share

Authors

RTRosemarie Tremblay‐LeMayNRNasrin RastgooMPMaryam Pourabdollah

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tremblay‐LeMay et al. (2018) studied this question.

synapsesocial.com/papers/6a1f3752d09bc027e4833011https://doi.org/10.1186/s40364-018-0148-5
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1c-Rel Regulates Ezh2 Expression in Activated Lymphocytes and Malignant Lymphoid Cells2014 · 37 citations
  2. 2Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control2017 · 111 citations
  3. 3Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors2015 · 82 citations
  4. 4Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas2018 · 140 citations
  5. 5EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas2011 · 122 citations